Rheumatology Unit, ASST-Fatebenefratelli L. Sacco University Hospital, University of Milan, Italy.
Rheumatology Unit, ATS Sardegna, P. Dettori Hospital, Tempio Pausania, Italy.
Clin Exp Rheumatol. 2020 Mar-Apr;38(2):337-342. doi: 10.55563/clinexprheumatol/xcdary. Epub 2020 Mar 22.
A severe outbreak of coronavirus disease 2019 (COVID-19) emerged in China in December 2019, and spread so rapidly that more than 200,000 cases have so far been reported worldwide; on January 30, 2020, the WHO declared it the sixth public health emergency of international concern. The two previously reported coronavirus epidemics (severe acute respiratory syndrome [SARS] and Middle East respiratory syndrome [MERS]) share similar pathogenetic, epidemiological and clinical features as COVID-19. As little is currently known about SARS-CoV-2, it is likely that lessons learned from these major epidemics can be applied to the new pandemic, including the use of novel immunosuppressive drugs.
2019 年 12 月，中国爆发了严重的 2019 冠状病毒病（COVID-19）疫情，传播速度如此之快，以至于目前全球已报告超过 20 万例病例；2020 年 1 月 30 日，世界卫生组织宣布其为第六次国际关注的公共卫生紧急事件。之前报告的两次冠状病毒疫情（严重急性呼吸综合征[SARS]和中东呼吸综合征[MERS]）与 COVID-19 具有相似的发病机制、流行病学和临床特征。由于目前对 SARS-CoV-2 知之甚少，因此很可能可以将从这些重大疫情中吸取的经验教训应用于新的大流行，包括使用新型免疫抑制剂。
